DOCSLIB.ORG

Pediatric Brain Tumors and Implications for Physical Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pediatric Brain Tumors and Implications for Physical Therapy 12/15/2018 PEDIATRIC CANCERS OBJECTIVES AND THE ROLE OF PHYSICAL THERAPY • Identify and describe common pediatric ALONG THE oncology diagnoses. CONTINUUM OF CARE • Recognize the associated side effects of medical Stacey Caviston PT, DPT, PCS treatments for pediatric cancers and their Kristen DeVirgilio PT, DPT impact on function. Megan Ryninger PT, DPT, PCS January 25, 2019 • Develop and implement effective physical therapy examinations, treatment strategies, and overall plan(s) of care for pediatric patients in all stages of cancer treatment. • Discuss the differences between pediatric and adult cancers. 1 ADULT VERSUS PEDIATRIC CANCERS • Pediatric cancers are not strongly linked to lifestyle factors • Less health co-morbidities lend to improved GENERAL response and tolerance of treatment OVERVIEW • Cancer treatment can have long term side effects Pediatric Cancers • More inpatient admissions COMMON PEDIATRIC CANCERS KEY STATISTICS • Leukemia • Pediatric cancers make up < 1% of all cancers • Brain and spinal cord tumors diagnosed each year • Neuroblastoma • Wilms tumor • An estimated 10,590 new cancer cases will be diagnosed among children 0 to 14 years of age in • Lymphoma (including both Hodgkin and Non the US in 2018. Hodgkin) • Rhabdomyosarcoma • Cancer is the second-leading cause of death • Retinoblastoma among children ages 1-14 years (after accidents), • Bone cancer (including osteosarcoma and Ewing accounting for 13% of deaths in 2015. sarcoma) 1 12/15/2018 INCIDENCE RATES INCIDENCE RATES American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018. American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018. ETIOLOGY GENERALIZED SIGNS AND SYMPTOMS • Inherited familial syndromes • Unusual mass or swelling • Neurofibromatosis type 1 • Paleness • Li-Fraumeni syndrome • Loss of energy • Genetic syndromes • Increase in bleeding or bruising • Down Syndrome • Persistent, localized pain or limping • Germline mutations • Prolonged/unexplained fever • Environmental factors • Frequent headaches often associated with • Ionizing radiation vomiting • Lifestyle factors • Sudden eye or vision changes • Not typically a factor in pediatric cases • Sudden unexplained weight loss GENERAL DIAGNOSTIC TESTS STAGING • Medical history and physical exam • Currently no national system for pediatrics • Blood tests • Bone marrow aspiration and biopsy • Staging systems vary by: • Lumbar puncture • Diagnosis • Biopsy • Trial group/current protocol • Chest x-ray • Computed tomography (CT) or positron emission tomography (PET) scan • Magnetic resonance imaging (MRI) • Ultrasound 2 12/15/2018 MEDICAL INTERVENTIONS CHEMOTHERAPY • Chemotherapy • Cytotoxic medications used to kill cancerous cells by: • Killing cancer cells • Radiation therapy • Stopping cancer cells from dividing • Most common methods of administration: • Surgery • Oral • Intravenous • Intrathecal • Steroids • Malignant cancers receive multiple chemotherapy agents via individualized road maps COMMON TYPES OF CHEMOTHERAPY CHEMOTHERAPY SIDE EFFECTS AGENTS Chemotherapy Agent Possible Side Effects Common Diagnoses Vincristine Hair loss, peripheral neuropathy, constipation, low blood Acute leukemia, Hodgkin’s/non-Hodgkin’s • Nausea/vomiting counts, nausea, vomiting, mouth sores, diarrhea, loss of lymphoma, neuroblastoma, appetite, taste changes, abdominal cramping rhabdomyosarcoma, Ewing’s sarcoma, • Fatigue Wilms’ tumor, multiple • Fever myeloma, chronic leukemias, thyroid cancers, brain tumors, and some blood • Pain disorders • Hearing loss Cisplatin Low blood counts, nausea, vomiting, kidney toxicity, low Hodgkin’s/non-Hodgkin’s lymphoma, magnesium/potassium/calcium, peripheral neuropathy, neuroblastoma, sarcomas • Anemia/neutropenia high frequency hearing loss, loss of appetite, taste changes, • Bruising/bleeding liver dysfunction, hair loss, changes in fertility • Diarrhea or constipation Etoposide Low blood counts, low platelet counts, hypotension, loss of Hodgkin’s and non-Hodgkin’s lymphoma, • Nerve/muscle effects fertility, nausea, vomiting, hair loss, mouth sores, diarrhea, Wilm’s tumor, rhabdomyosarcoma, Ewing’s poor appetite, nerve damage sarcoma, neuroblastoma, brain tumors, and • Secondary malignancies can be used for conditioning for bone marrow transplant • Hair loss • Mouth sores High dose methotrexate Low blood counts, mouth sores, poor appetite, nausea, Acute lymphoblastic leukemia, sarcomas, • Weight loss vomiting, kidney toxicity, kidney failure, skin rash, diarrhea, non-Hodgkin’s lymphoma, and cutaneous T hair loss, eye irritation, liver problems, radiation recall, loss of cell lymphoma • Infection fertility • Changes in appetite Doxorubicin Heart damage, fatigue, nausea, vomiting, mouth sores, bone Soft tissue and bone sarcomas, acute marrow suppression lymphoblastic leukemia, acute myeloid leukemia, Hodgkin lymphoma Ifosfamide Damage to lining of bladder, mouth sores, nausea, vomiting, Soft tissue and bone sarcoma nerve damage, blurred vision, hair loss RADIATION THERAPY TYPES OF RADIATION • Use of high energy particles or waves to destroy cancer cells by inhibiting cell growth and X-ray/photon Proton division • Total brain irrigation • Targets tumor at • Deposit energy in higher intensity • Method of administration depends on type and small packets along • Depth of energy is stage of cancer their path through the released and can be • External tissue controlled • Internal • Can damage healthy • Fewer short term and • Systemic tissue long term side effects • Decreases risk of secondary malignancies 3 12/15/2018 RADIATION THERAPY GENERAL SIDE DOSE DISTRIBUTION EFFECTS • Fatigue • Hair Loss • Integumentary changes • Immunosuppression Fowler JF. What can we expect from dose escalation using proton beams? Clin Oncol. 2003;15(1):S10-S15. • Secondary malignancies TYPES OF SURGERIES SURGERY • Biopsy • Curative • Palliative • Gross total resection • Relieve pain • Clear margins • Minimize symptoms • Gross total resection versus partial resection • Improve quality of life • Reconstruction • Limb salvage • Amputation SURGICAL SIDE EFFECTS STEROIDS • Pain • Corticosteroids are man-made drugs that work like cortisol, a natural hormone in your body. • Fatigue • Appetite loss • Prescribed as part of treatment or as a • Integumentary changes supportive measure • Numbness • Bleeding • Common corticosteroids used in pediatric • Infection cancer treatment: • Physical impairments • Dexamethasone • Prednisone • Cognitive impairments 4 12/15/2018 STEROID SIDE EFFECTS PEDIATRIC CANCER PROGNOSIS • Increased appetite • The 5-year relative survival for the most recent time • Weight gain period (2007-2013) is 83%, although rates vary considerably depending on cancer type, patient age, and • Muscle weakness other characteristics. • Mood swings • Depends on several factors including: • Nausea • Type of tumor • Insomnia • Location of tumor • High glucose levels • Grade of tumor • High blood pressure • Staging • Avascular necrosis (AVN) • Speed of growth • Hearing loss • Treatment options • Age of child • Immunosuppression • Childhood cancer survivors can experience late and long • Gastrointestinal issues term effects from treatment in a variety of body systems. BONE MARROW, STEM CELL, AND SURVIVAL RATES CORD BLOOD TRANSPLANTS • Healthy marrow or stem cells are infused into pt’s blood stream • Goal of transplant is engraftment • Indications • Patients with relapsed ALL and AML • Patients with life threatening disease • Patients with Neuroblastoma • Some patients with brain tumors American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018. BONE MARROW, STEM CELL, AND TRANSPLANT PROCESS CORD BLOOD TRANSPLANTS • Types of Transplant • Pre-transplant conditioning • Bone Marrow • High doses of chemo and or radiation • Stem Cells • Umbilical Cord Blood • Transplant • Cells are administered • Source of cells • Allogenic - Donor • Post-transplant • Autogenic - Self • Await engraftment • Syngenic - Identical twin • Usually 12-17 days 5 12/15/2018 BONE MARROW AND STEM CELL TRANSPLANT – SIDE EFFECTS • Graft vs. Host Disease (GVHD) • Mucositis • Nausea/Vomiting • Venous Occlusive Disease (VOD) • Steroid induced myopathy • Sterility SOLID TUMORS • Cardiac and pulmonary disease • High risk of life threatening infection • Secondary malignancies COMMON DIAGNOSES OSTEOSARCOMA • Osteosarcoma • Tumor cells arise from osteoblast cells and • Ewing’s Sarcoma primarily affect the ends of the long bones • Rhabdomyosarcoma • Most common malignant bone tumor in children • Neuroblastoma and adolescents • ~ 400 new pediatric cases each year in the United States • ~ 2% of childhood cancers • Common sites: • Distal femur • Proximal tibia • Proximal humerus OSTEOSARCOMA SIGNS AND OSTEOSARCOMA STAGING SYMPTOMS • Pain • Simplified • Stiffness or tenderness • Local • Progressively worse over time • Resectable • Wakes from sleep • Non-resectable • Swelling • Metastatic • Musculoskeletal Tumor Society (MSTS) staging • Palpable mass in arm or leg system • Difficulty walking or limp • Grade (G) Stage Grade Tumor Metastasis • Fracture • Extent of primary tumor (T) IA G1 T1 M0 • Metastases (M) • Fatigue IB G1 T2 M0 • TNM staging system IIA G2 T1 M0 • Weight loss • (T) Tumor IIB G2 T2 M0 G1 or T1 • Anemia • (N) Nodes III M1 • (M) Metastasized G2 orT2 • (G) Grade 6 12/15/2018 OSTEOSARCOMA TREATMENT OSTEOSARCOMA PROGNOSIS • Chemotherapy: Total 6 cycles • Positive Prognostic Factors • Neoadjuvant: Prior to surgery or radiation • 2 cycles
Load more

Recommended publications
  • Brain Tumors
    BRAIN TUMORS What kinds of brain tumors affect pets? Brain tumors occur relatively often in dogs and cats. The most common type of brain tumor is a meningioma, which originates from the layer surrounding the brain, called the meninges. Meningiomas are slow-growing benign tumors that are often present for months to years before clinical signs appear. Other common types in- clude glial cell tumors, which originate in the brain tissue, and choroid plexus tumors, which originate from the tissue in the brain that produces spinal fluid. Tumors in structures around the brain (like nasal tumors, skull tumors, and pituitary tumors) may also com- press the brain. Lymphoma is a type of cancer that can affect multiple parts of the brain and spine. What are the symptoms? Symptoms vary and depend on the size and location of the tumor. Common signs include changes in behavior, circling or pacing, staring into space, getting stuck in corners, and seizures. Other signs can include weakness, lack of alertness, difficulty eating or swallowing, and problems with the “vestibular system,” or system of bal- ance, such as lack of coordination, head tilt, leaning/circling/falling to one side, and abnormal eye movements. How are brain tumors diagnosed? An MRI scan produces an image of the brain that’s more detailed than a CT scan or x-ray and can identify a tumor. Often the appearance of the tumor on MRI suggests the type of tumor (i.e. meningioma vs lymphoma). However, a biopsy of the tumor is required to give a definitive diagnosis. In some cases, spinal fluid is collected to help diagnose lymphoma.
    [Show full text]
  • Neuro-Oncology
    Neuro-Oncology Neuro-Oncology 17:iv1–iv62, 2015. doi:10.1093/neuonc/nov189 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 Quinn T. Ostrom M.A., M.P.H.1,2*, Haley Gittleman M.S.1,2*, Jordonna Fulop R.N.1, Max Liu3, Rachel Blanda4, Courtney Kromer B.A.5, Yingli Wolinsky Ph.D., M.B.A.1,2, Carol Kruchko B.A.2, and Jill S. Barnholtz-Sloan Ph.D.1,2 1Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA 2Central Brain Tumor Registry of the United States, Hinsdale, IL USA 3Solon High School, Solon, OH USA 4Georgetown University, Washington D.C. USA 5Case Western Reserve University School of Medicine, Cleveland, OH USA *Contributed equally to this Report. Introduction for collection of central (state) cancer data as mandated in 1992 by Public Law 102-515, the Cancer Registries Amendment The objective of the CBTRUS Statistical Report: Primary Brain and Act.2 This mandate was expanded to include non-malignant Central Nervous System Tumors Diagnosed in the United States brain tumors diagnosed in 2004 and later with the 2002 in 2008-2012 is to provide a comprehensive summary of the passage of Public Law 107–260.3 CBTRUS researchers combine current descriptive epidemiology of primary brain and central the NPCR data with data from the SEER program4 of the NCI, nervous system (CNS) tumors in the United States (US) popula- which was established for national cancer surveillance in the tion. CBTRUS obtained the latest available data on all newly early 1970s.
    [Show full text]
  • The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors
    Review The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors Angelina Cistaro 1,2 , Domenico Albano 3 , Pierpaolo Alongi 4,* , Riccardo Laudicella 5 , Daniele Antonio Pizzuto 6 , Giuseppe Formica 5, Cinzia Romagnolo 7, Federica Stracuzzi 5, Viviana Frantellizzi 8 , Arnoldo Piccardo 1,2 and Natale Quartuccio 2,9 1 Nuclear Medicine Department, Ospedali Galliera, 16128 Genova, Italy; [email protected] (A.C.); [email protected] (A.P.) 2 AIMN Pediatric Study Group, 20159 Milan, Italy; [email protected] 3 Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy; [email protected] 4 Unit of Nuclear Medicine, Fondazione Istituto G. Giglio, 90015 Cefalù, Italy 5 Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, A.O.U. Policlinico G. Martino, University of Messina, 98125 Messina, Italy; [email protected] (R.L.); [email protected] (G.F.); [email protected] (F.S.) 6 Department of Nuclear Medicine, University Hospital Zürich, 8091 Zürich, Switzerland; [email protected] 7 Nuclear Medicine Unit, Ospedali Riuniti, Torrette di Ancona, 60126 Ancona, Italy; [email protected] 8 Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00161 Rome, Italy; [email protected] 9 Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, 90127 Palermo, Italy * Correspondence:
    [Show full text]
  • Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring
    cancers Review Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring Felix Behling 1,2,* , Johann-Martin Hempel 2,3 and Jens Schittenhelm 2,4 1 Department of Neurosurgery, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 2 Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany; [email protected] (J.-M.H.); [email protected] (J.S.) 3 Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 4 Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany * Correspondence: [email protected] Simple Summary: Meningiomas are benign tumors of the meninges and represent the most common primary brain tumor. Most tumors can be cured by surgical excision or stabilized by radiation therapy. However, recurrent cases are difficult to treat and alternatives to surgery and radiation are lacking. Therefore, a reliable prognostic marker is important for early identification of patients at risk. The presence of infiltrative growth of meningioma cells into central nervous system tissue has been identified as a negative prognostic factor and was therefore included in the latest WHO classification for CNS tumors. Since then, the clinical impact of CNS invasion has been questioned by different retrospective studies and its removal from the WHO classification has been suggested. Citation: Behling, F.; Hempel, J.-M.; There may be several reasons for the emergence of conflicting results on this matter, which are Schittenhelm, J. Brain Invasion in discussed in this review together with the potential and future perspectives of the role of CNS Meningioma—A Prognostic Potential invasion in meningiomas.
    [Show full text]
  • What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children
    cancer.org | 1.800.227.2345 About Brain and Spinal Cord Tumors in Children Overview and Types If your child has just been diagnosed with brain or spinal cord tumors or you are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children Research and Statistics See the latest estimates for new cases of brain and spinal cord tumors in children in the US and what research is currently being done. ● Key Statistics for Brain and Spinal Cord Tumors in Children ● What’s New in Research for Childhood Brain and Spinal Cord Tumors? What Are Brain and Spinal Cord Tumors in Children? Brain and spinal cord tumors are masses of abnormal cells in the brain or spinal cord 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 that have grown out of control. Are brain and spinal cord tumors cancer? In most other parts of the body, there's an important difference between benign (non- cancerous) tumors and malignant tumors (cancers1). Benign tumors do not invade nearby tissues or spread to distant areas, and are almost never life threatening in other parts of the body. Malignant tumors (cancers) are so dangerous mainly because they can spread throughout the body. Brain tumors rarely spread to other parts of the body, though many of them are considered malignant because they can spread through the brain and spinal cord tissue. But even so-called benign tumors can press on and destroy normal brain tissue as they grow, which can lead to serious or sometimes even life-threatening damage.
    [Show full text]
  • Adult Isocitrate Dehydrogenase–Mutant Brainstem Glioma: Illustrative Case
    J Neurosurg Case Lessons 1(12):CASE2078, 2021 DOI: 10.3171/CASE2078 Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case *Vincent C. Ye, MD,1 Alexander P. Landry, MD,1 Teresa Purzner, MD, PhD,1 Aristotelis Kalyvas, MD,1 Nilesh Mohan, MD,1 Philip J. O’Halloran, MD, PhD,1 Andrew Gao, MD,2 and Gelareh Zadeh, MD, PhD1,3 1Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada; 2Department of Pathology, University Health Network, Toronto, Ontario, Canada; and 3Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Ontario, Canada BACKGROUND Adult brainstem gliomas are rare entities that demonstrate heterogeneous biology and appear to be distinct from both their pediatric counterparts and adult supratentorial gliomas. Although the role of histone 3 mutations is being increasingly understood in this disease, the effectof isocitrate dehydrogenase (IDH) mutations remains unclear, largely because of limited data. OBSERVATIONS The authors present the case of a 29-year-old male with an IDH1-mutant, World Health Organization grade III anaplastic astrocytoma in the dorsal medulla, and they provide a review of the available literature on adult IDH-mutant brainstem glioma. The authors have amassed a cohort of 15 such patients, 7 of whom have survival data available. Median survival is 56 months in this small cohort, which is similar to that for IDH wild-type adult brainstem gliomas. LESSONS The authors’ work reenforces previous literature suggesting that the role of IDH mutation in glioma differs between brainstem and supratentorial lesions. Therefore, the authors advocate that adult brainstem gliomas be studied in terms of major molecular subgroups (including IDH mutant) because these gliomas may exhibit fundamental differences from each other, from pediatric brainstem gliomas, and from adult supratentorial gliomas.
    [Show full text]
  • Epidemiology and Survival of Patients with Brainstem Gliomas: a Population-Based Study Using the SEER Database
    ORIGINAL RESEARCH published: 11 June 2021 doi: 10.3389/fonc.2021.692097 Epidemiology and Survival of Patients With Brainstem Gliomas: A Population-Based Study Using the SEER Database † † Huanbing Liu 1 , Xiaowei Qin 1 , Liyan Zhao 2, Gang Zhao 1* and Yubo Wang 1* 1 Department of Neurosurgery, First Hospital of Jilin University, Changchun, China, 2 Department of Clinical Laboratory, Second Hospital of Jilin University, Changchun, China Background: Brainstem glioma is a primary glial tumor that arises from the midbrain, Edited by: pons, and medulla. The objective of this study was to determine the population-based Yaohua Liu, epidemiology, incidence, and outcomes of brainstem gliomas. Shanghai First People’s Hospital, China Methods: The data pertaining to patients with brainstem gliomas diagnosed between Reviewed by: 2004 and 2016 were extracted from the SEER database. Descriptive analyses were Kristin Schroeder, conducted to evaluate the distribution and tumor-related characteristics of patients with Duke Cancer Institute, United States Gerardo Caruso, brainstem gliomas. The possible prognostic indicators were analyzed by Kaplan-Meier University Hospital of Policlinico G. curves and a Cox proportional hazards model. Martino, Italy *Correspondence: Results: The age-adjusted incidence rate was 0.311 cases per 100,000 person-years Gang Zhao between 2004 and 2016. A total of 3387 cases of brainstem gliomas were included in our [email protected] study. Most of the patients were white and diagnosed at 5-9 years of age. The most Yubo Wang [email protected] common diagnosis confirmed by histological review was ependymoma/anaplastic †These authors have contributed ependymoma. The median survival time was 24 months.
    [Show full text]
  • Meningioma ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Meningioma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Meningioma Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit advocacy organization dedicated solely to brain tumor research. For nearly 45 years, the ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Santosh Kesari, MD, PhD, FANA, FAAN chair of department of translational neuro- oncology and neurotherapeutics, and Marlon Saria, MSN, RN, AOCNS®, FAAN clinical nurse specialist, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA; and Albert Lai, MD, PhD, assistant clinical professor, Adult Brain Tumors, UCLA Neuro-Oncology Program, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2017 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Meningioma INTRODUCTION Although meningiomas are considered a type of primary brain tumor, they do not grow from brain tissue itself, but instead arise from the meninges, three thin layers of tissue covering the brain and spinal cord.
    [Show full text]
  • Recent Advances in the Treatment of Gliomas – Comprehensive Brain Tumor Center
    RECENT ADVANCES IN NEUROSURGERY Recent Advances in the Treatment of Gliomas – Comprehensive Brain Tumor Center STEVEN A. TOMS, MD, MPH; NIKOLAOS TAPINOS, MD, PhD ABSTRACT development of electric current loco-regional antimitotic Gliomas are a class of primary brain tumors arising from therapy (“tumor-treating fields”) led to the first reported the supporting structures of the brain, the astrocytes and survivals exceeding 20 months7. oligodendrocytes, which range from benign lesions to In the United States alone, 12,000 new cases of GBM are its most malignant form, the glioblastoma. Treatment diagnosed each year8. One reason cited for the failure to for these lesions includes maximal surgical resection, improve survival has been the presence of a robust blood- radiotherapy, and chemotherapy. Recently, novel thera- brain barrier within the tumor, which impedes delivery of pies such as immune modulatory therapies and electrical traditional cytotoxic and novel molecular therapies9. Most field treatment of the most malignant form, the glioblas- chemotherapeutic agents are hydrophilic, and do not pene- toma, have shown promise in improving survival. We trate the blood brain barrier well. Attempts to deliver che- will review recent advances in clinical trials, explore the motherapeutic molecules into the brain have included both role of multimodal care in brain tumor therapy, as well osmotic, chemical, and ultrasound mediated opening of the as explore advances in molecular biology and nanotech- blood brain barrier to improve drug delivery, but none have nology which offer new hope for treatment of this class improved clinical outcomes10. A novel method to bypass of disease. this barrier, (i.e., convection enhanced delivery), met with KEYWORDS: glioblastoma, immunotherapy, tumor success in delivering high drug concentrations of hydro- treating fields, nanotechnology, drug delivery philic drugs to brain tumors and led to several clinical trials.
    [Show full text]
  • Intensity Modulated Radiation Therapy for Tumors of the Central Nervous System
    Corporate Medical Policy Intensity Modulated Radiation Therapy for Tumors of the Central Nervous System File Name: intensity_modulated_radiation_therapy_for_tumors _of_the_central_nervous_system Origination: 10/2010 Last CAP Review: 5/2021 Next CAP Review: 5/2022 Last Review: 5/2021 Description of Procedure or Service Radiation therapy is an integral component in the treatment of many brain tumors, both benign and ma lignant. Intensity modulated ra diation therapy (IMRT) has been proposed a s a method of radiation thera py that a llows a dequate radiation therapy to the tumor while minimizing the ra diation dose to surrounding normal tissues and critical structures. Background Radiation therapy and brain tumors The sta ndard a pproach to the treatment of brains tumors depends on the type and location of tumor. For gliobla stoma multiforme (GBM), a malignant high-gra de tumor, trea tment is multimodal, with surgical resection followed by adjuvant radiation therapy (RT) a nd chemotherapy. For benign and low-grade brain tumors, gross total resection remains the primary goal. However, radiation therapy may be used in selected cases. Some examples are when total resection is not possible, when a more conservative surgical approach may be necessary to achieve long-term trea tment goals, a nd with a typical tumors that may need ra diotherapy even a fter gross total resection to reduce the risk of local recurrence. Therefore, radiation therapy, either definitive or in the postoperative a djuvant setting, remains an integral component in the management of residual, recurrent, a nd/or progressive benign a nd low-grade brain tumors for maximizing local control. Brain metastases occur in up to 40% of adults with cancer and can shorten survival and detract from quality of life.
    [Show full text]
  • The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
    International Journal of Molecular Sciences Review The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy Fiona A. Desland and Adília Hormigo * Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Department of Neurology, Box 1137, 1 Gustave L. Levy Pl, New York, NY 10029-6574, USA; fi[email protected] * Correspondence: [email protected] Received: 28 August 2020; Accepted: 29 September 2020; Published: 5 October 2020 Abstract: Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor in adults. Its aggressive nature is attributed partly to its deeply invasive margins, its molecular and cellular heterogeneity, and uniquely tolerant site of origin—the brain. The immunosuppressive central nervous system (CNS) and GBM microenvironments are significant obstacles to generating an effective and long-lasting anti-tumoral response, as evidenced by this tumor’s reduced rate of treatment response and high probability of recurrence. Immunotherapy has revolutionized patients’ outcomes across many cancers and may open new avenues for patients with GBM. There is now a range of immunotherapeutic strategies being tested in patients with GBM that target both the innate and adaptive immune compartment. These strategies include antibodies that re-educate tumor macrophages, vaccines that introduce tumor-specific dendritic cells, checkpoint molecule inhibition, engineered T cells, and proteins that help T cells engage directly with tumor cells. Despite this, there is still much ground to be gained in improving the response rates of the various immunotherapies currently being trialed. Through historical and contemporary studies, we examine the fundamentals of CNS immunity that shape how to approach immune modulation in GBM, including the now revamped concept of CNS privilege.
    [Show full text]
  • Current Diagnosis and Treatment of Oligodendroglioma
    Neurosurg Focus 12 (2):Article 2, 2002, Click here to return to Table of Contents Current diagnosis and treatment of oligodendroglioma HERBERT H. ENGELHARD, M.D., PH.D. Departments of Neurosurgery, Bioengineering, and Molecular Genetics, The University of Illinois at Chicago, Illinois Object. The strategies used to diagnose and treat oligodendroglial tumors have changed significantly over the past decade. The purpose of this paper is to review the topic of oligodendroglioma, emphasizing the new developments. Methods. Information was obtained by conducting a Medline search in which the term oligodendroglioma was used. Recent editions of standard textbooks were also studied. Because of tools such as magnetic resonance imaging, oligodendrogliomas are being diagnosed earlier, and they are being recognized more frequently histologically than in the past. Seizures are common in these patients. Functional mapping and image-guided surgery may now allow for a safer and more complete resection, especially when tumors are located in difficult areas. Genetic analysis and positron emission tomography may provide data that supplement the standard diagnostic tools. Unlike other low-grade gliomas, patients in whom residual or recurrent oligodendroglioma (World Health Organization Grade II) is present may respond to chemotherapy. Although postoperative radiotherapy prolongs survival of the patient, increasingly this therapeutic modality is being delayed until tumor recurrence, espe- cially if a gross-total tumor resection has been achieved. Oligodendrogliomas are the first type of brain tumor for which “molecular” characterization gives important information. The most significant finding is that allelic losses on chro- mosomes 1p and 19q indicate a favorable response to chemotherapy. Conclusions. Whereas surgery continues to be the primary treatment for oligodendroglioma, the scheme for post- operative therapy has shifted, primarily because of the lesion’s relative chemosensitivity.
    [Show full text]